SCHEMBL6315543

SCHEMBL6315543

NC(=O)c1c(-c2ccsc2)noc1NC(=O)c1cc(F)cc(F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNIK Q9UKE5 1/20 0.39
RET P07949 1/20 0.39
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA4 P22748 1/20 0.37
CA7 P43166 1/20 0.37
CHEK2 O96017 4/20 0.37
IKBKE Q14164 2/20 0.36
TBK1 Q9UHD2 2/20 0.36
MAPT P10636 1/20 0.36
IKBKB O14920 2/20 0.36
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TP53 P04637 1/20 0.35
HPGD P15428 1/20 0.35
CASP1 P29466 1/20 0.35
RAB9A P51151 1/20 0.35
HSD17B10 Q99714 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316805 0.90 CA1 (0.46) TNIKRETCA1CA2CA4
SCHEMBL6316187 0.85 KIT (0.46) RETCA1CA2CA4CA7
SCHEMBL6318554 0.85 MAPK14 (0.47) CA1CA2CA4CA7TBK1
SCHEMBL6316204 0.84 NPC1 (0.39) TNIKRETCHEK2IKBKETBK1
SCHEMBL6316062 0.83 NPC1 (0.41) RETIKBKETBK1NPC1KDR
SCHEMBL6323363 0.83 P2RY14 (0.47) TNIKRETCHEK2IKBKETBK1
SCHEMBL6315365 0.82 NPC1 (0.43) KDM4ENPC1ALDH1A1TP53RAB9A
SCHEMBL6322739 0.82 FLT3 (0.46) RETKDM4ENPC1ALDH1A1TP53
SCHEMBL6316770 0.81 LMNA (0.53) MAPTKDM4ENPC1ALDH1A1RAB9A
SCHEMBL6317590 0.81 SMN1; SMN2 (0.49) RETCA1CA2KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 TNIK 248/4885RET 768/4885CA1 2406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.